Inventor · disambiguated record
Yuhong Zhou
Also filed as: ZHOU YUHONG
17 granted patents·10 pending applications·108 citations·filing 1999–2024
93Inventor score
Files withGENAERA CORP7BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD6MORPHOTEK INC4NICOLAIDES NICHOLAS C2CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD1
Top patents by PatentIndex Score
27 records- 0191US8278065B2Polynucleotides encoding anti-GD2 antibodiesNICOLAIDES NICHOLAS C·Filed 2009·Granted Oct 2, 2012·11 cites·28 claims
- 0289US7807382B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2008·Granted Oct 5, 2010·11 cites·8 claims
- 0388US8507657B2Anti-GD2 antibodiesNICOLAIDES NICHOLAS C·Filed 2012·Granted Aug 13, 2013·10 cites·6 claims
- 0486US7345051B2Mucin synthesis inhibitorsGENAERA CORP·Filed 2002·Granted Mar 18, 2008·30 cites·27 claims
- 0584US6737427B2Mucin synthesis inhibitorsGENAERA CORP·Filed 2001·Granted May 18, 2004·19 cites·59 claims
- 0679US10994021B1Tetravalent antibody-drug conjugates and use thereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2020·Granted May 4, 2021·1 cites·15 claims
- 0777US7504409B2Mucin synthesis inhibitorsGENAERA CORP·Filed 2004·Granted Mar 17, 2009·9 cites·58 claims
- 0874US8895000B2Methods for inhibiting the binding of endosialin to ligandsZHOU YUHONG·Filed 2010·Granted Nov 25, 2014·3 cites·28 claims
- 0974US2024342304A1Tetravalent Antibody-Drug Conjugates and Use ThereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2024·Application pending·0 cites
- 1073US9505842B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2014·Granted Nov 29, 2016·1 cites·5 claims
- 1169US6716603B2Nucleic acids encoding a chloride channel proteinGENAERA CORP·Filed 2002·Granted Apr 6, 2004·3 cites·18 claims
- 1267US11951173B2Tetravalent antibody-drug conjugates and use thereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2021·Granted Apr 9, 2024·0 cites·13 claims
- 1365US2024002527A1Anti-cd73 antibody, antibody-drug conjugate, and use thereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1465US2024075154A1Engineered antibody, antibody-drug conjugate, and use thereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1565US2023414781A1Anti-cd276 antibody, antibody-drug conjugate, and use thereofBLISS BIOPHARMACEUTICAL HANGZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1664US8956832B2Cells expressing anti-GD2 antibodies and methods related theretoMORPHOTEK INC·Filed 2013·Granted Feb 17, 2015·0 cites·4 claims
- 1762US7919248B2Methods for the modulation of IL-13LIGAND PHARM INC·Filed 2008·Granted Apr 5, 2011·0 cites·12 claims
- 1861US10053509B2Methods for inhibiting the binding of endosialin to ligandsMORPHOTEK INC·Filed 2016·Granted Aug 21, 2018·0 cites·2 claims
- 1959US2009068185A1Asthma associated factors as targets for treating atopic allergies including asthma and related disordersHOLROYD KENNETH J·Filed 2007·Application pending·0 cites
- 2056US12377089B2Quinoline derivative used for soft tissue sarcoma combination therapyCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Granted Aug 5, 2025·0 cites·10 claims
- 2156US7211254B2Methods for treating ICACC protein associated diseasesGENAERA CORP·Filed 2004·Granted May 1, 2007·0 cites·12 claims
- 2256US6576434B1Methods for identification of agents which modulate chloride channel activityGENAERA CORP·Filed 1999·Granted Jun 10, 2003·10 cites·32 claims
- 2353US2004219149A1Methods for the modulation of il-13Filed 2002·Application pending·0 cites
- 2447US2013305396A1Engineered human endosialin-expressing rodentsGRASSO LUIGI·Filed 2011·Application pending·0 cites
- 2546US2002165244A1Mucin synthesis inhibitorsFiled 2001·Application pending·0 cites
- 2646US2002147216A1Mucin synthesis inhibitorsFiled 2001·Application pending·0 cites
- 2745US2008096981A1Antibodies against inducible TH2 cell factorsGENAERA CORP·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yuhong Zhou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →